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Abstract In Alzheimer disease brain the activities of protein
phosphatase (PP)-2A and PP-1 are decreased and the micro-
tubule-associated protein tau is abnormally hyperphosphorylated
at several sites at serine/threonine. Employing rat forebrain slices
kept metabolically active in oxygenated artificial CSF as a
model system, we investigated the role of PP-2A/PP-1 in the
regulation of some of the major abnormally hyperphosphorylated
sites of tau and the protein kinases involved. Treatment of the
brain slices with 1.0 WM okadaic acid inhibitedV65% of PP-2A
and produced hyperphosphorylation of tau at Ser 198/199/202,
Ser 396/404 and Ser 422. No significant changes in the activities
of glycogen synthase kinase-3 (GSK-3) and cyclin dependent
protein kinases cdk5 and cdc2 were observed. Calyculin A (0.1
WM) inhibited V50% PP-1, V20% PP-2A, 50% GSK-3 and
V30% cdk5 but neither inhibited the activity of cyclin AMP
dependent protein kinase A (PKA) nor resulted in the hyperphos-
phorylation of tau at any of the above sites. Treatment of brain
slices with 1 WM okadaic acid plus 0.1 WM calyculin A inhibited
V100% of both PP-2A and PP-1, V80% of GSK-3, V50% of
cdk5 and V30% of cdc2 but neither inhibited PKA nor resulted
in the hyperphosphorylation of tau at any of the above sites.
These studies suggest (i) that PP-1 upregulates the phosphoryla-
tion of tau at Ser 198/199/202 and Ser 396/404 indirectly by
regulating the activities of GSK-3, cdk5 and cdc2 whereas PP-
2A regulates the phosphorylation of tau directly by dephos-
phorylation at the above sites, and (ii) that a decrease in the PP-
2A activity leads to abnormal hyperphosphorylation of tau at Ser
198/199/202, Ser 396/404 and Ser 422. ß 2000 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Alzheimer disease (AD) is a neurodegenerative disorder
characterized clinically by a progressive and irreversible dete-
rioration of cognitive functions and neuropathologically by
the presence of two major histopathological lesions, neuritic
senile plaques (SP) and intraneuronal neuro¢brillary tangles
(NFTs). NFTs consist of paired helical ¢laments (PHFs) the
major protein subunit of which is the hyperphosphorylated
microtubule-associated protein tau [1^4]. Unlike normal tau
which promotes microtubule assembly and stabilizes the struc-
ture of microtubules [5^7] the abnormally hyperphosphory-
lated tau from AD brain sequesters normal microtubule-asso-
ciated proteins and causes inhibition and disruption of
microtubules in vitro [8^10].
Tau is abnormally hyperphosphorylated at least at 21 sites
in AD and about half of tau sites are serine/threonine fol-
lowed by proline [11,12]. These Ser/Thr^Pro sites are among
the major abnormally phosphorylated sites in AD tau. Thus,
only proline-directed protein kinase (PDKs) will be expected
to phosphorylate tau at these sites. In vitro and cell culture
studies have shown that GSK-3 and cdk5/cdc2 are likely to be
the major PDPKs that phosphorylate tau [13^16].
All sites of tau phosphorylation including the abnormally
hyperphosphorylated sites seen in the AD brain are at Ser/Thr
residues [11,12]. Hence the candidate phosphatases are re-
stricted to phosphoseryl/phosphothreonyl protein phospha-
tases (PP) such as PP-1, PP-2A, PP2B and PP2C. In vitro
studies have shown that abnormally phosphorylated tau iso-
lated from AD brain can be dephosphorylated by PP-2A,
PP2B and to a less extent by PP-1 but not by PP2C [17^20].
Moreover, a decrease of V20% in the activities of PP-2A and
PP-1 have been found in AD brain as compared to age-
matched controls [21,22]. However, whether this decrease in
PP-2A/PP-1 activities contributes to the abnormal hyperphos-
phorylation of tau by merely a reduction in dephosphoryla-
tion of this protein or also in addition indirectly by stimulat-
ing the activities of one or more tau kinases is not understood.
Studies of serine^threonine PPs has been facilitated by the
availability of potent inhibitors of these enzymes. Among
them are okadaic acid and calyculin A which inhibit PP-1
and PP-2A [23,24]. Okadaic acid inhibits PP-2A with an
IC50 of V1 nM; it also inhibits PP-1, but at a 10- to 100-
fold higher concentration [24^26]. Calyculin A is structurally
di¡erent from okadaic acid and inhibits PP-1 and PP-2A with
roughly equal potency (IC50 of 0.1V1.0 nM) [24^26].
In this study, employing okadaic acid and calyculin A, we
investigated in metabolically active rat brain slices the role of
PP-2A and PP-1 in the regulation of the activities of GSK-3,
cdk5, cdc2 and PKA and the phosphorylation of tau at sev-
eral of the sites known to be abnormally hyperphosphorylated
in AD. We have found that in rat forebrain (i) the inhibition
of PP-2A has no signi¢cant e¡ect on the activities of GSK-3,
cdk5, cdc2 and PKA and the hyperphosphorylation of tau at
Ser 198/199/202, Ser 396/404 and Ser 422 is largely due to
reduced dephosphorylation by this phosphatase at these sites;
(ii) that PP-1 upregulates the activities of GSK-3, cdk5 and
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cdc2; and (iii) that GSK-3 and or cdk5/cdc2 phosphorylate
tau at Ser 198/199/202, Ser396/404 and Ser 422.
2. Materials and methods
2.1. Preparation and treatment of rat brain slices with phosphatase
inhibitors
Female Wistar rats (Charles River Breeding Laboratories),
3 months old, were injected intraperitoneally with 75 mg/kg nembutal,
followed by heart puncture. The brain was rapidly removed and
cooled in oxygenated (95% O2/5% CO2) arti¢cial cerebrospinal £uid
(aCSF) containing 150 mM NaCl, 2 mM CaCl2, 1.2 mM MgSO4, 0.5
mM KH2PO4, 1.5 mM K2HPO4 and 10 mM glucose at pH 7.4. The
cerebellum and brain stem were discarded, the forebrain kept and
sliced vertically and cross sectionally at every 500 Wm using a
Mcllwain tissue chopper (Brinkmann Instruments). The slices were
washed two times with aCSF and then incubated at 35‡C in aCSF
either alone or in the presence of 1.0 WM okadaic acid, 0.1 WM caly-
culin A (both from RBI, Natick, MA, USA) or 1.0 WM okadaic acid
along with 0.1 WM calyculin A. The incubation medium was contin-
uously oxygenated. After di¡erent periods of time, slices were re-
moved, washed two times and homogenized at 4‡C using a Te£on
glass homogenizer in 50 mM Tris^HCl, pH 7.0, 10 mM L-mercapto-
ethanol containing a cocktail of protease inhibitors (1.0 mM EDTA,
0.1 mM phenylmethyl sulfonyl £uoride, 2 mM benzamidine and 2 Wg/
ml each of aprotinin, leupeptin and pepstatin). The homogenate was
then divided into two parts, one was centrifuged at 16 000Ug for 20
min and the supernatant was used to assay activities of PP-2A and
PP-1. The rest of the homogenate was diluted 1:1 with a phosphatase
inhibitor cocktail (20 mM L-glycerophosphate, 2 mM Na3VO4 and
100 mM NaF, pH 7.0) and stored at 380‡C and used for Western
blots and for assaying the activities of GSK-3, cdk5, cdc2 and PKA,
as described below.
2.2. Western blots
Samples were subjected to 10% SDS^PAGE as described originally
by Laemmli [27]. The protein bands were electrophoretically trans-
ferred on Immobilon-P membrane (Millipore, Bedford, MA, USA).
The blots were developed with various antibodies to tau (Table 1)
followed by 125I-radiolabeled secondary antibodies (Amersham Phar-
macia Biotech, Inc) and the bands were visualized and quantitated
with a phosphorimager (Fuji ¢lm BAS-1500) and TINA 2.0 software
(raytest IsotopenmeLgera«te GmbH).
2.3. PP assay
PP activity towards [32P]phosphorylase a was determined by the
liberation of 32P as previously described [19]. A PP-1 speci¢c inhibitor,
phosphorylated Inhibitor-1 [28], was included in the assay for PP-2A
activity. PP-1 activity was calculated by subtracting the PP-2A activity
from the total phosphorylase phosphatase activity (PP-1 and PP-2A)
assayed in the absence of Inhibitor-1.
2.4. Protein kinase assay
The activities of cdc2, cdk5 and GSK-3 were assayed after immu-
noprecipitation of these enzymes from rat brain extract with appro-
priate speci¢c antibodies. The rat brain extract (16 000Ug), 50 Wg
protein was mixed with 2 Wg of antibodies directed against cdc2 ki-
nase, cdk5 (both antibodies from Santa Cruz Biotechnology, Heidel-
berg, Germany) or GSK-3 (polyclonal R133d; [29]) in 50 mM Tris,
pH 7.4, 150 mM NaCl, 10 mM NaF, 1 mM Na3VO4, 2 mM EGTA,
1.0 mM PMSF, 5 Wg/ml leupeptin, 5 Wg/ml aprotinin, 2 Wg/ml pep-
statin and 25 Wg/ml phosphoramidon. After incubation at 4‡C over-
night, 30 Wl of immobilized protein G suspension (Pierce, Rockford,
IL, USA) was added and the reaction mixture was constantly mixed
for 2^4 h. Then the mixture was centrifuged and the precipitates were
washed three times with immunoprecipitation bu¡er. Precipitates were
suspended in 25 Wl of bu¡er containing 30 mM Tris, pH 7.4, 10 mM
NaF, 10 mM MgCl2, 1 mM Na3VO4, 2 mM EGTA, 10 mM L-mer-
captoethanol, 200 WM [Q-32P]ATP and 1 mg/ml histone (Sigma, St.
Louis, MO, USA) or 0.5 mg/ml myelin basic protein (Sigma, St.
Louis, MO, USA). Histone was employed for the cdc2 and cdk5
assays, and myelin basic protein was used as a substrate to assay
GSK-3 activity. The reaction was initiated by the addition of
[Q-32P]ATP and incubation was carried out at 30‡C for 10 min for
cdc2/cdk5 assay or for 15 min in the case of GSK-3 assay. The re-
action was stopped by addition of 25 Wl of 300 mM phosphoric acid
and a volume of 10 Wl of reaction mixture was then spotted in trip-
licates on phosphocellulose paper (Pierce, Rockford, IL, USA). The
¢lters were washed three times with 75 mM phosphoric acid, dried
and counted by Cerenkov radiation. Phosphorylation in the absence
of exogenous substrate was subtracted from each total kinase activity.
The activity of PKA was assayed in 25 Wl reaction mixture containing
brain extract (0.05 mg/ml), 70 mM NaHPO4, pH 6.8, 14 mM MgCl2,
1.4 mM EGTA, 5 WM cyclic-AMP (Sigma, St Louis, MO, USA), 30
WM malantide (Sigma, St Louis, MO, USA) and 200 WM [Q-32P]ATP.
The reaction was initiated by adding [Q-32P]ATP, followed by incuba-
tion at 30‡C for 10 min. The rest of the procedure is the same as
described above for cdk5/cdc2 and GSK-3 assays.
3. Results
3.1. Inhibition of PP-2A and PP-1 activities by okadaic acid
and calyculin A in rat forebrain
In order to understand the molecular mechanism by which
the decrease in PP-2A/PP-1 activities found in AD forebrain
might lead to the abnormal hyperphosphorylation of tau, we
employed as a model system rat forebrain slices kept meta-
bolically active in oxygenated aCSF. The activities of PP-2A/
PP-1 in the brain slices were inhibited by treating them with
Fig. 1. Inhibition of PP-2A/PP-1 in rat brain slices. Rat brain slices
were treated with aCSF as a control, and with either 1.0 WM oka-
daic acid, 0.1 WM calyculin A or both for 1^3 h. The tissue was
then homogenized and the 16 000Ug extract prepared for assaying
the activities of PP-2A and PP-1 as described in Section 2. PP activ-
ity was determined using 32P-phosphorylase a as a substrate. Data
are expressed as a percentage (mean þ S.D.) of the phosphatase ac-
tivity detected in aCSF-treated rat brain slices used as a control.
Okadaic acid inhibits PP-2A activity by V65% (P6 0.002) during
1^3 h treatment but had a minimal e¡ect on PP-1 activity. Calycu-
lin A inhibited V50% (P6 0.003) of PP-1 activity and about 20%
(P6 0.016) of PP-2A activity. In rat brain slices treated with both
okadaic acid and calyculin A, neither PP-2A nor PP-1 activities
were detectable.
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okadaic acid and calyculin A. The treatment of the brain
slices with 1.0 WM okadaic acid inhibited V65% of PP-2A
in 1h and the level of inhibition remained constant up to 3 h
studied (Fig. 1). However, by this treatment no signi¢cant
inhibition of PP-1 was observed. These ¢ndings are in agree-
ment with previous studies where up to V70% inhibition of
PP-2A with 5 WM okadaic acid was achieved in rat brain slices
[30]. Calyculin A which is chemically di¡erent from okadaic
acid inhibited V50% of PP-1 and V20% of PP-2A in the
brain slices during 3 h. These e¡ects of okadaic acid and
calyculin A in rat forebrain are considerably weaker than
those reported previously in vitro and in cultured cells where
nanomolar concentrations of the drugs were found to com-
pletely inhibit these phosphatases [23,31]. As observed previ-
ously (Bennecib et al., in preparation) a combination of 1 WM
okadaic acid and 0.1 WM calyculin A, however, completely
inhibited both PP-2A and PP-1 in the brain slices (Fig. 1).
3.2. Regulation of the activities of tau kinases and the
phosphorylation of tau by PP-1 and PP-2A
The activities of PP-2A and PP-1 are compromised in the
brain of patients with AD and the abnormally hyperphos-
phorylated tau from AD brain can be dephosphorylated in
vitro by PP-2A at Ser 198/199/202, Ser 396/404 [18] and Ser
422 (unpublished data). Several protein kinases are regulated
by reversible phosphorylation and some of these kinases are
substrates for PP-2A/PP-1. Thus, a decrease in PP-2A or PP-1
or both could result in the hyperphosphorylation of tau either
directly from a decrease in dephosphorylation or from an
upregulation of one or more tau kinase activity. In the present
study, we investigated in brain the role of these two phospha-
tases both in the regulation of the phosphorylation of tau at
the abnormal sites cited above and in the regulation of the
protein kinases involved. The treatment of the rat brain slices
with 1.0 WM okadaic acid which inhibited V65% of PP-2A
Fig. 2. E¡ect of inhibition of PP-2A activity on the activities of GSK-3, cdk5, cdc2 and phosphorylation of tau at these speci¢c sites. Rat brain
slices were incubated in either oxygenated aCSF as controls or with 1.0 WM okadaic acid, and the changes in phosphorylation status of tau
were examined after 1 or 3 h of incubation. A: Homogenates of rat brain slices after treatment for 1 or 3 h were subjected to Western blots
developed with phosphorylation dependent tau antibodies (Table 1) as indicated in the right side of each panel. Okadaic acid induced hyper-
phosphorylation of tau at Ser 198/199/202, Ser 396/404 and Ser 422 as detected by antibodies Tau-1 (before and after treatment of the blot
with alkaline phosphatase), PHF1 and R145d respectively. The immunoreactivity at Ser 198/199/202 with Tau-1 antibody decreased in rat brain
slices treated with okadaic acid due to phosphorylation at this epitope. The level of total tau as detected with 92e was not a¡ected in rat brain
slices treated with okadaic acid. Not shown in this ¢gure, no change was detected at Thr 231/Ser 235 as determined with M4 antibody. B: Im-
munoblots such as in Fig. 1A were scanned and the immunoreactivity obtained with each antibody was normalized against the total level of
tau detected by 92e antibody. Data are expressed as (mean þ S.D.) immunoreactivity per unit of tau. After 1 h of treatment the level of phos-
phorylation was increased to V3.5-fold (P6 0.005) at Ser 198/199/202 (Tau-1), s 2-fold (P6 0.014) at Ser 396/404 (PHF1) and V1.5-fold
(P6 0.017) at Ser 422 (R145d) in okadaic acid-treated rat brain slices (black bars) compared to aCSF samples (open bars). The phosphoryla-
tion of tau at Ser 198/199/202 was obtained by subtracting the immunoreactivity detected with Tau-1 antibody from the total immunoreactivity
detected with the same antibody in blots pretreated with alkaline phosphatase. The immunoreactivity, which indicates the level of phosphoryla-
tion, was then normalized with the total tau immunoreactivity. The immunoreactivity obtained with PHF1 or R145d was normalized with anti-
body 92 to total tau. Not shown in this ¢gure, no signi¢cant change was noticeable with antibody M4 directed against Thr 231/Ser 235. C:
The activities of GSK-3, cdc2 and cdk5 were assayed after immunoprecipitation from 16 000Ug rat brain extract of these enzymes as described
in Section 2. Data are expressed as a percentage (mean þ S.D.) of the kinase activity detected in aCSF-treated rat brain slices used as a control.
The activities of GSK-3 (toward myelin basic protein), cdc2 and cdk5 (toward histone) were not signi¢cantly a¡ected in brain slices after treat-
ment with okadaic acid.
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(see Fig. 1) resulted in a signi¢cant increase in the phosphor-
ylation of tau at Ser 198/199/202, Ser 396/404 and Ser 422
(Fig. 2A,B). Neither any changes in the level of total tau
(Fig. 2A, staining with antibody 92e) nor its phosphorylation
at Thr 231/Ser 235 (¢gure not shown) were observed. Further-
more, assays of GSK-3, cdk5 and cdc2 activities in the im-
munoprecipitates of these enzymes from the 16 000Ug extract
of the okadaic acid treated or control-treated brain slices re-
vealed no signi¢cant changes in the activities of these protein
kinases (Fig. 2C). These ¢ndings suggested that PP-2A regu-
lated the phosphorylation of tau at Ser 198/199/202, Ser 396/
404 and Ser 422 in rat brain.
Treatment of the brain slices with 0.1 WM calyculin A which
inhibited V50% of PP-1 and V20% of PP-2A (see Fig. 1)
resulted in 1 h in V40% inhibition of GSK-3 and V30%
inhibition of cdk5 and no signi¢cant e¡ect on the activities
of cdc2 and PKA (Fig. 3A). However, no signi¢cant changes
in the level of tau phosphorylation at either Ser 198/199/202,
Ser 396/404 (Fig. 3B) or Ser 422 (results not shown) were
observed, suggesting that PP-1 was little involved in the de-
phosphorylation of tau at these sites.
The rat brain slices treated with a combination of 1.0 WM
Fig. 3. The e¡ect of inhibition of PP-1 and PP-2 with calyculin A
on the activities of GSK-3, cdk5, cdc2 and PKA and the phosphor-
ylation of tau. Rat brain slices were treated in aCSF as controls or
with 0.1 WM calyculin A for 30 or 60 min. A: The activities of
GSK-3, cdc2 and cdk5 were assayed as in Fig. 2C. The kinase ac-
tivity of calyculin A-treated samples (black bars) was expressed as
the percentage (mean þ S.D.) of the activity of the control sample
(open bars). After 60 min of treatment, GSK-3 activity was de-
creased by V40% (P6 0.008). Cdk5 activity was decreased by
V30% (P6 0.022) at 30 min and the inhibition remained constant
with time up to the 60 min studied. The activities of cdc2 and PKA
were not signi¢cantly a¡ected in rat brain-treated with calyculin A.
B: Changes in tau phosphorylation were investigated using phos-
phorylation dependent antibodies as in Fig. 2C. No alteration in
tau phosphorylation at any of the sites studied was observed in rat
brain slices treated with calyculin A. Not shown in this ¢gure, no
signi¢cant changes were observed in the phosphorylation of tau at
Thr 231/Ser 235 by antibody M4, and at Ser 422 by antibody R145.
Fig. 4. E¡ect of inhibition of PP-1 and PP-2A activities with 0.1
WM calyculin A plus 1.0 WM okadaic acid on the activities of GSK-
3, cdk5, cdc2 and PKA, and the phosphorylation of tau in rat fore-
brain slices A: Rat brain slices were treated in aCSF as controls or
with 0.1 WM calyculin A plus 1.0 WM okadaic acid for 30 or 60
min. The activities of GSK-3, cdc2 and cdk5 were assayed as in
Fig. 2C. The kinase activity of inhibitor-treated brain slices (black
bars) was expressed as the percentage (mean þ S.D.) of the activity
of the aCSF-treated slices (open bars). The activity of GSK-3 de-
creased V40% (P6 0.004) in 30 min and V80% (P6 0.001) in 1 h
treatment. Cdk5 activity was inhibited by V50% (P6 0.012) at 30
min and the inhibition was maintained up to the 60 min studied. A
decrease of V30% (P6 0.010) in cdc2 activity was observed at 30
and 60 min. No signi¢cant change in PKA activity was detected.
B: Changes in tau phosphorylation were investigated using phos-
phorylation dependent antibodies as in Fig. 2C. No alteration in
tau phosphorylation was observed in rat brain slices treated with ca-
lyculin A. Not shown in this ¢gure, no signi¢cant changes were ob-
served in the phosphorylation of tau at Thr 231/Ser 235 by anti-
body M4 and at Ser 422 by antibody R145.
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okadaic acid and 0.1 WM calyculin A, which completely in-
hibited both PP-2A and PP-1 activities (see Fig. 1) produced
V50% and V80% inhibition of GSK-3 activity by 30 and 60
min, respectively (Fig. 4A). The okadaic acid plus calyculin A
treatment also inhibited V50% of cdk5 and V30% of cdc2 in
30 min which persisted up to 60 min studied. However, no
signi¢cant change in the activity of PKA between the drug-
treated and aCSF-treated control brain slices was observed
(Fig. 4A). Quantitative 125I-Western blots of the brain slices
developed with tau antibodies did not reveal any signi¢cant
changes in either the levels or the phosphorylation of tau at
Ser 198/199/202, Ser 396/404 (Fig. 4B), Ser 422 and Thr 231/
Ser 235 (data not shown). These ¢ndings suggested that the
activities of GSK-3 and cdk5/cdc2 in brain are regulated by
PP-1 and one or more of these kinases are involved in the
phosphorylation of tau at Ser 198/199/202 and Ser 396/404
but PP-1 does not appear to dephosphorylate tau at these
sites. The phosphorylation of tau at Thr 231/Ser 235 as de-
termined by immunostaining with the phosphorylation depen-
dent antibody M4 was weak in aCSF-treated control brain
slices. Neither of the above treatments with PP-2A/PP-1 in-
hibitors produced any increase in the phosphorylation of tau
at Thr 231/Ser 235 (¢gure not shown) suggesting that tau at
this site is not dephosphorylated by either PP-2A or PP-1.
4. Discussion
Identi¢cation of the protein kinases and phosphatases in-
volved in the generation of abnormally phosphorylated tau is
critical to understanding the pathogenesis of AD. Although
the mechanism leading to hyperphosphorylation of tau is still
unclear, growing evidence suggests that one or more PP activ-
ities might be responsible. The present study suggests (i) that
in forebrain PP-2A regulates the phosphorylation of tau at
Ser 198/199/202, Ser 396/404 and Ser 422 directly by dephos-
phorylating these sites; (ii) that tau is phosphorylated at
above sites by GSK-3 and or cdk5/cdc2, (iii) that PP-1 upre-
gulates the activities of GSK-3, cdk5 and cdc2 but has no
e¡ect on PKA activity; and (iv) that PP-2A has no signi¢cant
e¡ect on the activities of GSK-3, cdk5, cdc2 or PKA. These
¢ndings suggest that the abnormal hyperphosphorylation of
tau at Ser 198/199/202, Ser 396/404 and Ser 422 seen in AD
are most likely the result of the decreased PP-2A activity.
Treatment of the brain slices with 1.0 WM okadaic acid
which inhibited V65% of PP-2A activity and showed no in-
hibition of PP-1 resulted in the hyperphosphorylation of tau
at Ser 198/199/202, Ser 396/404 and Ser 422 but not at Thr
231/Ser 235. Furthermore, this treatment of the brain slices
did not a¡ect the activity of GSK-3, cdk5 or cdc2. In contrast,
the treatment of the brain slices with 0.1 WM calyculin A,
which inhibited V50% of PP-1 and V20% of PP-2A, pro-
duced V50% inhibition of GSK-3, V30% inhibition of cdk5
and V20% of cdc2 and did not result in any signi¢cant
change in the phosphorylation of tau at the above sites. These
studies suggest that PP-2A and not PP-1 dephosphorylates tau
at Ser 198/199/202, Ser 396/404 and Ser 422. Consistent with
our previous in vitro studies which showed dephosphorylation
of tau at Thr 231/Ser 235 by PP-2B and not by PP-2A or PP-1
[17^19], the present study shows that this site is not dephos-
phorylated by either PP-2A or PP-1 in forebrain.
While inhibition of the PP-2A activity by okadaic acid did
not have any e¡ect on the activities of GSK-3, cdk5 or cdc2,
inhibition of PP-1 activity by calyculin A and by calyculin A
plus okadaic acid resulted in a PP-1 inhibition dependent in-
hibition of the above kinases. These ¢ndings together with the
hyperphosphorylation of tau observed by inhibition of PP-2A
alone (see above) suggest that PP-1 upregulates the activities
of GSK-3, cdk5 and cdc2 and does not dephosphorylate tau
at either of the sites studied. The activities of all the three
PDPKs investigated in the present study i.e. GSK-3, cdk5
and cdc2 are known to be regulated by phosphorylation.
The activity of cdk5 which is enriched in adult brain, espe-
cially neurons [32^35] is regulated both by p35/p25 [33,34] and
by phosphorylation (reviewed by Morgan [36]). Phosphoryla-
tion of cdk5 at Thr 14 leads to its inhibition [37]. In the
present study inhibition of PP-1 activity decreased the cdk5
activity to V50%. Since the cdk5 activity also depends on the
binding of its activator p35/p25, we assayed the level of p35/
p25 by quantitative 125I-Western blots and found no signi¢-
cant change (data not shown), suggesting that the decrease in
cdk5 activity in the PP-1-inhibited brain slices was not due to
any decrease in the level of this activator. Thus, the present
study suggests that PP-1 might upregulate the activity of cdk5
by dephosphorylating it at Thr 14.
Cdc2 is subject to both positive and negative regulation by
phosphorylation [38]. Cdc2 requires phosphorylation by a sec-
ond protein kinase, known as CDK-activating kinase (CAK)
at Thr 161 (reviewed by Solomon, [39]). CAK is a nuclear
protein kinase in the CDK family in which cdk7 is complexed
to cyclin H [39]. Interestingly, CAK activity itself requires
phosphorylation of cdk7 at Thr 176 by another protein ki-
nase, CAK activating kinase [40,41]. P-Thr 161 can be de-
phosphorylated by PP-2A in vitro [42,43]. Phosphorylation
of cdc2 at Thr 14 or Tyr 15 negatively regulates the enzyme
[44]. The major PP that dephosphorylates the cdc2 inhibitory
sites is cdc25 [38,45]. Cdc25 is a dual speci¢city PP that can
dephosphorylate both pThr14 and pTyr15. In the present
study only V30% inhibition of cdc2 was observed when the
activities of PP-1 and PP-2A were V100% inhibited in the
brain slices treated with okadaic acid plus calyculin A. Caly-
culin A alone (V50% inhibition of PP-1 and V20% inhibi-
tion of PP-2A) or okadaic acid alone (V65% inhibition of
Table 1
Tau antibodies employed and their site-speci¢c phosphorylation dependence
Antibody Speci¢city Sites Reference
92e Un+P Grundke-Iqbal et al., 1988 [51]
Tau-1 UnP Ser 198/199/202 Grundke-Iqbal et al., 1986 [2] Liu et al., 1993 [52]
12E8 P Ser 262/356 Seubert et al., 1995 [53]
M4 P Thr 231/Ser 356 Hasegawa et al., 1995 [54]
PHF1 P Ser 396/404 Otvos et al., 1994 [55]
R145 P Ser 422 Tanaka et al., 1998 [31]
unP, unphosphorylated epitope; P, phosphorylated epitope. All antibodies except 92e were monoclonal.
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PP-2A) did not induce any signi¢cant decrease in cdc2 activ-
ity. These results suggest that either the treatment of brain
slices with okadaic acid plus calyculin A results in some inhi-
bition of cdc25 or PP-1 also dephosphorylates cdc2 at Thr 14
but poorly. Alternatively, PP-1 might be involved in the reg-
ulation upstream of cdc2.
Phosphorylation of GSK-3K at Ser 21 and GSK-3L at Ser 9
results in inhibition of the kinase [46^50]. GSK-3 is also con-
stitutively phosphorylated at Tyr 279 in GSK-3K and at Tyr
216 in GSK-3L and dephosphorylation of these residues re-
sults in inactivation of the enzyme. In the present study
V65% inhibition of PP-2A activity by 1.0 WM okadaic acid
in rat brain slices produced no signi¢cant changes in GSK-3
activity. These ¢ndings are in agreement with our previous
study where treatment of SY5Y neuroblastoma-cultured cells
with okadaic acid that completely inhibited PP-2A activity did
not result in any signi¢cant change in GSK-3 activity [31].
However, unexpectedly in the present study the inhibition of
PP-1 activity by calyculin A alone or calyculin A plus okadaic
acid inhibited up to V80% of GSK-3 activity. This unex-
pected e¡ect of PP-1 on GSK-3 probably involves some up-
stream regulation the nature of which remains to be deter-
mined.
In conclusion the present study in forebrain suggests that
tau is phosphorylated at Ser 198/199/202, Ser 396/404 and Ser
422 by GSK-3 and or cdk5/cdc2 and is dephosphorylated by
PP-2A. PP-1 upregulates the activities of GSK-3, cdk5 and
cdc2. In AD brain the hyperphosphorylation of tau produced
by the decrease in PP-2A activity probably more than o¡ sets
the decrease in the phosphorylation of tau at the above sites
produced by a decrease in PP-1 activity through downregula-
tion of the activities of GSK-3, cdk5 and cdc2. Phosphoryla-
tion of tau at Thr 231/Ser 235 does not appear to be regulated
by PP-2A. These ¢ndings taken together with our recent study
in which we found that PP-2A upregulates the cytosolic CaM-
KII activity and the phosphorylation of tau at Ser 262/356 in
forebrain (Bennecib et al., in preparation) suggests that PP-2A
probably plays a major role in the abnormal hyperphosphor-
ylation of tau. Thus, PP-2A is a promising therapeutic target
for AD and related taupathies that are characterized by the
neuro¢brillary degeneration associated with the abnormally
hyperphosphorylated tau.
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